This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
by Zacks Equity Research
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
by Kinjel Shah
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
Pfizer (PFE) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the most recent trading session, Pfizer (PFE) closed at $23.27, indicating a -2.29% shift from the previous trading day.
Microsoft Q4 Earnings & Revenues Beat on Cloud Business Expansion
by Zacks Equity Research
MSFT's fourth-quarter fiscal 2025 results reflect strength in the AI business and Copilot adoption, backed by accelerating growth in its Azure cloud infrastructure unit.
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
by Zacks Equity Research
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?
by Kanishka Das
MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Tops Q2 Earnings Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of +5.97% and -0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Ekta Bagri
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
by Kinjel Shah
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
by Kinjel Shah
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
by Kinjel Shah
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Increased Expenses Affect Bristol Myers' Performance?
by Ekta Bagri
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
by Zacks Equity Research
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.